Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 36 for “"Differentiation therapy"”.
-
Studying the effect of differentiation therapy on osteosarcoma
Lack of terminal differentiation is widely observed in bone cancer patients, yielding fast-proliferating, immature cancer cells. A potential strategy for cancer treatment is differentiation therapy, where the aim is to “reprogramme” cancer cell behaviour, by inducing differentiation. Around 150 …
-
Heparan Sulfate Signaling in Neuroblastoma Pathogenesis and Differentiation Therapy
… factors and their receptors coordinate neuronal differentiation during development, yet their roles in the embyronal tumor neuroblastoma, where differentiation is a validated treatment strategy, remain unclear. The neuroblastoma tumor stroma is thought to suppress neuroblast growth via release of …
-
MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY
… the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in identifying combinations of transcription factors (TFs) and drugs which induce granulocytic differentiation of the NB4 acute promyelocytic …
-
Discovering Novel Druggable Targets for Neuroblastoma Differentiation Therapy from the Human Kinome
… growth and survival through aberrant signaling. Differentiation therapy aims to promote the maturation of neuroblastoma cells, with cellular neurite outgrowth and cell growth arrest considered markers for this differentiation. This study investigates the hypothesis that targeting specific kinase …
-
Modeling normal and malignant hematopoiesis in vitro. To screen for extrinsic regulators and differentiation therapy.
… myeloid leukemia (AML) cells and HSC to identify differentiation therapy of AML (papers I and II), improve culture conditions of HSC (paper III), and for investigating synthetic lethality in AML (paper IV). Thus, the common thread of the four papers included in this thesis is the use of OP9M2 …
-
The Expression Of Mkrn1, An E3 Ubiquitin Ligase For Telomerase Reverse Transcriptase, Is Induced With Differentiation Therapy In Leukemia
… arrested at G1. In this model system of cellular differentiation hTERT mRNA levels and telomerase activity decrease drastically and quickly. We hypothesized that the differentiation of HL-60 induced by ATRA would be accompanied by an increase in MKRN1 levels. MKRN1 mRNA and protein levels were …
-
DISSECTING RECEPTORS AND SIGNALING PATHWAYS DRIVING ALL-TRANS RETINOIC ACID-INDUCED DIFFERENTIATION OF THE ACUTE MYELOID LEUKEMIA CELL LINE, HL-60: IN PURSUIT OF ACTIONABLE TARGETS FOR EXPANSION OF DIFFERENTIATION THERAPY
Differentiation therapy based on all-trans retinoic acid (RA) has dramatically improved patient outcomes for those suffering from acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), but has been much less effective in treating other types of AML. This may be at least in …
-
Overcoming The Differentiation Block: Mechanisms Of Retinoic Acid-Induced Differentiation, Resistance, And Lineage Selection In Myeloid Leukemia Progenitor Cells
Differentiation induction therapy aims to "reform, rather than retaliate" like conventional chemotherapeutic methods. The most successful differentiation therapy has been treatment of t(15;17)-positive acute promyelocytic leukemia (APL) patients with retinoic acid (RA), an embryonic morphogen and …
-
Evaluation of the role of autophagy in acute myeloid leukaemic cell differentiation
… survival is poor. Pharmacological overcoming the differentiation block seen in AML is an attractive avenue of therapy, termed ‘differentiation therapy’. The best example of this is the use of all-trans-retinoic acid (ATRA) in the treatment of acute promyelocytic leukaemia (APL). The …
-
Identifying Target Genes of MiR-506-3p that Mediate Its Differentiation-Inducing Activity and Developing Differentiation-Inducing MiR-506-3p Analogs
… recurrence due to failed curative treatment. Differentiation therapy is a form of therapy that induces cell differentiation in neuroblastoma cells and decreases cell proliferation. MiR-506-3p, a microRNA that is endogenously expressed in human cells, has exhibited dramatic …
-
ΑΝΑΠΤΥΞΗ ΤΩΝ ΟΥΡΕΙΔΟ ΠΑΡΑΓΩΓΩΝ ΤΗΣ ΠΥΡΙΔΙΝΗΣ ΩΣ ΝΕΩΝ ΧΗΜΙΚΩΝ ΕΠΑΓΩΓΕΩΝ ΤΗΣ ΔΙΑΦΟΡΟΠΟΙΗΣΗΣ ΝΕΟΠΛΑΣΜΑΤΙΚΩΝ ΚΥΤΤΑΡΩΝ ΚΑΙ ΑΝΑΛΥΣΗ ΤΟΥ ΜΟΡΙΑ...
… AND EFFECTIVE INDUCERS THAT CAN BE USED FOR DIFFERENTIATION THERAPY OF CANCER AND ANALYSIS OF THE MECHANISM(S) OF ACTION OF UDPS AT CELLULAR AND MOLECULAR LEVEL. THE RESULTS OBTAINED INDICATE THAT: A) AMONG THE VARIOUS UDPS PREPARED, SOME INDUCED ERYTHROID DIFFERENTIATION OF …
-
Using human pluripotent stem cells to discover differentiation inducers for the treatment of acute myeloid leukemia
… LSCs possess enhanced self-renewal and blocked differentiation capacity, leading to an accumulation of immature blood cells. Currently, conventional treatments for AML consist of non-selective cytotoxic chemotherapy (e.g., cytarabine), which targets rapidly dividing bulk tumour cells but fails …
-
Mechanisms and therapy of differentiation resistance in cancer: neuroblastoma as a model
… inhibitory effect of N-Myc on neuroblastoma cell differentiation. N-Myc acted as a transrepressor by recruiting the HDAC-1 protein to the TG2 gene core promoter. In neuroblastoma-bearing N-Myc transgenic mice, HDACI treatment induced TG2 expression and demonstrated marked anti-tumour activity in …
-
ASCL1, ACTIVATED BY LMO1 AND MYCN ONCOGENE, IS A MASTER REGULATOR OF DIFFERENTIATION PROGRAM IN ADRENERGIC NEUROBLASTOMA
… cells to retinoic acid treatment to induce differentiation, thus providing a novel insight for neuroblastoma differentiation therapy. Moreover, ASCL1 directly regulated the expression of other CRC genes. Taken together, ASCL1 is a critical downstream target of LMO1 and MYCN and is an …
-
Investigating the Differential Responses of Neuroblastoma Cell Lines to MiR-506-3p and Retinoic Acid Treatment
… than 15% of cancer-related pediatric deaths. Differentiation therapy is a commonly used method in treating advanced stages where cancer cells are pushed to undergo differentiation into their mature form. Retinoic acid (RA) is the only differentiation agent currently being used in clinical …
-
ROLE OF OSTEOBLASTS AND ADIPOCYTES IN PROTECTION AGAINST ALL TRANS RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA
… of all-trans retinoic acid (ATRA) to chemotherapy for treating APL. That said, it was soon realized that single-agent ATRA was not sufficient to prevent relapse in these patients, though the reason for this clinical observation was not apparent. Over the last decade, it was hypothesized …
-
Establishing Neuroblastoma Cell Lines that are Resistant to Differentiation-Inducing Agents
… develop after the failure of neural crest differentiation. Even though retinoic acid has been used in the treatment of neuroblastoma, the incidence of recurrence of the tumor cells is around 50%. Synthetic mimics of miR-506-3p, a microRNA, induce neuroblastoma cell differentiation …
-
Signaling through CD44 affects cell cycle progression and c-Jun expression in acute myeloid leukemia cells
… monoclonal antibodies have been shown to induce differentiation and inhibit the proliferation of human acute myeloid leukemia (AML) cells, and c-Jun is involved in the regulation of these processes. The effects of anti-CD44 monoclonal antibody A3D8, on myeloid cells were associated with specific …
-
Compare the Sensitivity of Neuroblastoma Cell Lines to Differentiation Inducing MIR-506-3P and Retinoic Acid Treatment
… than classical mutation driven oncogenesis. Differentiation therapy with retinoic acid is standard in maintenance regimens, yet many high-risk NB cases show limited responses, highlighting the need for alternative differentiation inducers. MicroRNAs (miRNAs) regulate lineage programs; among …
-
Novel Neuroblastoma Differentiating Agents
… survival rate is 40-50% after treatment. The differentiation therapy with retinoic acid (RA) is at the forefront of approaches to treat neuroblastoma; however, more than half of patients experience recurrence suggesting resistance to RA. There is currently no alternative outside of …
Page 1 of 2